Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2012 (2012), Article ID 150107, 10 pages
http://dx.doi.org/10.1155/2012/150107
Review Article

New and Old Mechanisms Associated with Hypertension in the Elderly

Cardiovascular Research Unit, Cardiology Department, Hospital Clínico San Carlos, Madrid 28040, Spain

Received 21 July 2011; Accepted 19 August 2011

Academic Editor: Blas Gil Extremera

Copyright © 2012 Petra J. Mateos-Cáceres et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. J. Elliott, “Management of hypertension in the very elderly patient,” Hypertension, vol. 44, no. 6, pp. 800–804, 2004. View at Publisher · View at Google Scholar · View at PubMed
  2. H. H. L. Ooi, P. L. Coleman, J. Duggan, and Y. M. O'Meara, “Treatment of hypertension in the elderly,” Current Opinion in Nephrology and Hypertension, vol. 6, no. 5, pp. 504–509, 1997. View at Google Scholar
  3. W. B. Kannel and J. Cobb, “Framingham study: risk factors in the cohort aged 65 and older,” in Prevention of Cardiovascular Heart Disease in the Elderly, B. Lewis, M. Mancini, and E. Farinaro, Eds., pp. 3–18, Current Medical Literature, London, UK, 1991. View at Google Scholar
  4. J. L. Izzo, Hypertension Primer: The Essentials of High Blood Pressure, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 4th edition, 2008.
  5. W. B. Kannel, “Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile,” American Heart Journal, vol. 138, no. 3, pp. S205–S210, 1999. View at Google Scholar · View at Scopus
  6. A. Amery, P. Brixko, and D. Clement, “Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial,” The Lancet, vol. 1, no. 8442, pp. 1349–1354, 1985. View at Google Scholar · View at Scopus
  7. J. L. Probstfield, “Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP),” Journal of the American Medical Association, vol. 265, no. 24, pp. 3255–3264, 1991. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Staessen, R. Fagaard, L. Thijs et al., “Morbidity and mortality in the placebo controlled European Trial on Isolated Systolic Hypertension in the Elderly (SYSTEUR),” The Lancet, vol. 360, pp. 757–764, 1997. View at Google Scholar
  9. C. J. Bulpitt, A. E. Fletcher, A. Amery et al., “The hypertension in the very elderly trial (HYVET),” Journal of Human Hypertension, vol. 8, no. 8, pp. 631–632, 1994. View at Google Scholar · View at Scopus
  10. E. G. Lakatta and D. Levy, “Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease,” Circulation, vol. 107, no. 1, pp. 139–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. S. S. Najjar and E. G. Lakatta, “Vascular aging: from molecular to clinical cardiology,” in Principles of Molecular Cardiology, W. C. Patterson and M. Runge, Eds., pp. 517–547, Humana Press, Totowa, NJ, USA, 2005. View at Google Scholar
  12. E. G. Lakatta, “Central arterial aging and the epidemic of systolic hypertension and atherosclerosis,” Journal of the American Society of Hypertension, vol. 1, no. 5, pp. 302–340, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. R. Virmani, A. P. Avolio, W. J. Mergner et al., “Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis: comparison between occidental and Chinese communities,” American Journal of Pathology, vol. 139, no. 5, pp. 1119–1129, 1991. View at Google Scholar · View at Scopus
  14. S. Moncada, R. M. J. Palmer, and E. A. Higgs, “Nitric oxide: physiology, pathophysiology, and pharmacology,” Pharmacological Reviews, vol. 43, no. 2, pp. 109–142, 1991. View at Google Scholar · View at Scopus
  15. S. Moncada and A. Higgs, “The L-arginine-nitric oxide pathway,” New England Journal of Medicine, vol. 329, no. 27, pp. 2002–2012, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. A. Csiszar, M. Wang, E. G. Lakatta, and Z. Ungvari, “Inflammation and endothelial dysfunction during aging: role of NF-κB,” Journal of Applied Physiology, vol. 105, no. 4, pp. 1333–1341, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. Q. Shi, K. Aida, J. L. Vandeberg, and L. W. Xing, “Passage-dependent changes in baboon endothelial cells—relevance to in vitro aging,” DNA and Cell Biology, vol. 23, no. 8, pp. 502–509, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. Chinellato, L. Pandolfo, E. Ragazzi et al., “Effect of age on rabbit aortic responses to relaxant endothelium-dependent and endothelium-independent agents,” Blood Vessels, vol. 28, no. 5, pp. 358–365, 1991. View at Google Scholar · View at Scopus
  19. M. Gerhard, M. A. Roddy, S. J. Creager, and M. A. Creager, “Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans,” Hypertension, vol. 27, no. 4, pp. 849–853, 1996. View at Google Scholar · View at Scopus
  20. T. Koga, Y. Takata, K. Kobayashi, K. Fujii, T. Nagao, and M. Fujishima, “Age-related changes in P2-purinergic receptors on vascular smooth muscle and endothelium,” Hypertension, vol. 19, no. 3, pp. 286–289, 1992. View at Google Scholar · View at Scopus
  21. H. Moritoki, T. Yoshikawa, T. Hisayama, and S. Takeuchi, “Possible mechanisms of age-associated reduction of vascular relaxation caused by atrial natriuretic peptide,” European Journal of Pharmacology, vol. 210, no. 1, pp. 61–68, 1992. View at Publisher · View at Google Scholar · View at Scopus
  22. M. R. Cernadas, L. S. De Miguel, M. García-Durán et al., “Expression of constitutive and inducible nitric oxide synthases in the vascular wall of young and aging rats,” Circulation Research, vol. 83, no. 3, pp. 279–286, 1998. View at Google Scholar · View at Scopus
  23. A. López-Farré, L. S. De Miguel, C. Caramelo et al., “Role of nitric oxide in autocrine control of growth and apoptosis of endothelial cells,” American Journal of Physiology, vol. 272, no. 2, pp. H760–H768, 1997. View at Google Scholar · View at Scopus
  24. G. Mancia, G. Seravalle, and G. Grassi, “Systolic blood pressure: an underestimated cardiovascular risk factor,” Journal of Hypertension, vol. 20, supplement 5, pp. S21–S27, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. S. S. Najjar, A. Scuteri, V. Shetty et al., “Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore longitudinal study of aging,” Journal of the American College of Cardiology, vol. 51, no. 14, pp. 1377–1383, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. T. D. Giles, B. C. Berk, H. R. Black et al., “Expanding the definition and classification of hypertension,” Journal of Clinical Hypertension, vol. 7, no. 9, pp. 505–512, 2005. View at Google Scholar · View at Scopus
  27. J. D. Adams, S. K. Mukherjee, L. K. Klaidman, M. L. Chang, and R. Yasharel, “Apoptosis and oxidative stress in the aging brain,” Annals of the New York Academy of Sciences, vol. 786, pp. 135–151, 1996. View at Google Scholar · View at Scopus
  28. S. I. Usami, Y. Takumi, S. Fujita, H. Shinkawa, and M. Hosokawa, “Cell death in the inner ear associated with aging is apoptosis?” Brain Research, vol. 747, no. 1, pp. 147–150, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. S. Galis, G. K. Sukhova, M. W. Lark, and P. Libby, “Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques,” Journal of Clinical Investigation, vol. 94, no. 6, pp. 2493–2503, 1994. View at Google Scholar · View at Scopus
  30. H. R. Warner, R. J. Hodes, and K. Pocinki, “What does cell death have to do with aging?” Journal of the American Geriatrics Society, vol. 45, no. 9, pp. 1140–1146, 1997. View at Google Scholar · View at Scopus
  31. K. Asai, R. K. Kudej, Y. T. Shen et al., “Peripheral vascular endothelial dysfunction and apoptosis in old monkeys,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 6, pp. 1493–1499, 2000. View at Google Scholar · View at Scopus
  32. A. J. Donato, I. Eskurza, A. E. Silver et al., “Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-κB,” Circulation Research, vol. 100, no. 11, pp. 1659–1666, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. C. A. Hamilton, M. J. Brosnan, M. McIntyre, D. Graham, and A. F. Dominiczak, “Superoxide excess in hypertension and aging a common cause of endothelial dysfunction,” Hypertension, vol. 37, no. 2, pp. 529–534, 2001. View at Google Scholar · View at Scopus
  34. A. Csiszar, Z. Ungvari, J. G. Edwards et al., “Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function,” Circulation Research, vol. 90, no. 11, pp. 1159–1166, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Csiszar, Z. Ungvari, A. Koller, J. G. Edwards, and G. Kaley, “Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries,” FASEB Journal, vol. 17, no. 9, pp. 1183–1185, 2003. View at Google Scholar · View at Scopus
  36. A. Csiszar, M. Wang, E. G. Lakatta, and Z. Ungvari, “Inflammation and endothelial dysfunction during aging: role of NF-κB,” Journal of Applied Physiology, vol. 105, no. 4, pp. 1333–1341, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. M. Helenius, M. Hänninen, S. K. Lehtinen, and A. Salminen, “Aging-induced up-regulation of nuclear binding activities of oxidative stress responsive NF-kB transcription factor in mouse cardiac muscle,” Journal of Molecular and Cellular Cardiology, vol. 28, no. 3, pp. 487–498, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. T. Finkel and N. J. Holbrook, “Oxidants, oxidative stress and the biology of ageing,” Nature, vol. 408, no. 6809, pp. 239–247, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. J. Uribarri, W. Cai, M. Peppa et al., “Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging,” Journals of Gerontology A, vol. 62, no. 4, pp. 427–433, 2007. View at Google Scholar · View at Scopus
  40. J. W. Baynes and S. R. Thorpe, “Role of oxidative stress in diabetic complications: a new perspective on an old paradigm,” Diabetes, vol. 48, no. 1, pp. 1–9, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. A. Soro-Paavonen, W. Z. Zhang, K. Venardos et al., “Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase,” Journal of Hypertension, vol. 28, no. 4, pp. 780–788, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. A. Gugliucci and M. Bendayan, “Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells,” Diabetologia, vol. 39, no. 2, pp. 149–160, 1996. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Shanmugam, J. L. Figarola, Y. Li, P. M. Swiderski, S. Rahbar, and R. Natarajan, “Proinflammatory effects of advanced lipoxidation end products in monocytes,” Diabetes, vol. 57, no. 4, pp. 879–888, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. R. Bucala, K. J. Tracey, and A. Cerami, “Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes,” Journal of Clinical Investigation, vol. 87, no. 2, pp. 432–438, 1991. View at Google Scholar · View at Scopus
  46. T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787–790, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. S. F. Yan, R. Ramasamy, Y. Naka, and A. M. Schmidt, “Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond,” Circulation Research, vol. 93, no. 12, pp. 1159–1169, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. H. Vlassara, W. Cai, J. Crandall et al., “Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15596–15601, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. J. Uribarri, W. Cai, M. Peppa et al., “Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging,” Journals of Gerontology A, vol. 62, no. 4, pp. 427–433, 2007. View at Google Scholar · View at Scopus
  50. M. Peppa and S. A. Raptis, “Advanced glycation end products and cardiovascular disease,” Current Diabetes Reviews, vol. 4, no. 2, pp. 92–100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Soro-Paavonen, W. Z. Zhang, K. Venardos et al., “Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase,” Journal of Hypertension, vol. 28, no. 4, pp. 780–788, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. D. C. Throckmorton, A. P. Brogden, B. Min, H. Rasmussen, and M. Kashigarian, “PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products,” Kidney International, vol. 48, no. 1, pp. 111–117, 1995. View at Google Scholar · View at Scopus
  53. F. Monacelli, A. Poggi, D. Storace et al., “Effects of valsartan therapy on protein glycoxidation,” Metabolism, vol. 55, no. 12, pp. 1619–1624, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. Y. Saisho, N. Komiya, and H. Hirose, “Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan,” Diabetes Research and Clinical Practice, vol. 74, no. 2, pp. 201–203, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. J. Campisi, S. H. Kim, C. S. Lim, and M. Rubio, “Cellular senescence, cancer and aging: the telomere connection,” Experimental Gerontology, vol. 36, no. 10, pp. 1619–1637, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. E. H. Blackburn, “Switching and signaling at the telomere,” Cell, vol. 106, no. 6, pp. 661–673, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. E. H. Blackburn, “Telomere states and cell fates,” Nature, vol. 408, no. 6808, pp. 53–56, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. G. Pérez-Rivero, M. P. Ruiz-Torres, J. V. Rivas-Elena et al., “Mice deficient in telomerase activity develop hypertension because of an excess of endothelin production,” Circulation, vol. 114, no. 4, pp. 309–317, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. S. Demissie, D. Levy, E. J. Benjamin et al., “Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study,” Aging Cell, vol. 5, no. 4, pp. 325–330, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. A. L. Fitzpatrick, R. A. Kronmal, J. P. Gardner et al., “Leukocyte telomere length and cardiovascular disease in the cardiovascular health study,” American Journal of Epidemiology, vol. 165, no. 1, pp. 14–21, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. S. Brouilette, R. K. Singh, J. R. Thompson, A. H. Goodall, and N. J. Samani, “White cell telomere length and risk of premature myocardial infarction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 842–846, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. R. S. Vasan, S. Demissie, M. Kimura et al., “Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham heart study,” Circulation, vol. 117, no. 9, pp. 1138–1144, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. Z. Yang, X. Huang, H. Jiang et al., “Short telomeres and prognosis of hypertension in a Chinese population,” Hypertension, vol. 53, no. 4, pp. 639–645, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. T. Kunieda, T. Minamino, J. I. Nishi et al., “Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway,” Circulation, vol. 114, no. 9, pp. 953–960, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. B. Assmus, C. Urbich, A. Aicher et al., “HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes,” Circulation Research, vol. 92, no. 9, pp. 1049–1055, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. S. M. Bode-Böger, J. Martens-Lobenhoffer, M. Täger, H. Schröder, and F. Scalera, “Aspirin reduces endothelial cell senescence,” Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1226–1232, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. M. Satoh, Y. Ishikawa, Y. Takahashi, T. Itoh, Y. Minami, and M. Nakamura, “Association between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease,” Atherosclerosis, vol. 198, no. 2, pp. 347–353, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. G. L. Hoetzer, G. P. Van Guilder, H. M. Irmiger, R. S. Keith, B. L. Stauffer, and C. A. DeSouza, “Aging, exercise, and endothelial progenitor cell clonogenic and migratory capacity in men,” Journal of Applied Physiology, vol. 102, no. 3, pp. 847–852, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. E. J. Kushner, O. J. MacEneaney, B. R. Weil, J. J. Greiner, B. L. Stauffer, and C. A. DeSouza, “Aging is associated with a proapoptotic endothelial progenitor cell phenotype,” Journal of Vascular Research, vol. 48, no. 5, pp. 408–414, 2011. View at Publisher · View at Google Scholar · View at PubMed
  70. A. J. Van Zonneveld and T. J. Rabelink, “Endothelial progenitor cells: biology and therapeutic potential in hypertension,” Current Opinion in Nephrology and Hypertension, vol. 15, no. 2, pp. 167–172, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. G. Giannotti, C. Doerries, P. S. Mocharla et al., “Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction,” Hypertension, vol. 55, no. 6, pp. 1389–1397, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. S. Wassmann, N. Werner, T. Czech, and G. Nickenig, “Improvement of endothelial function by systemic transfusion of vascular progenitor cells,” Circulation Research, vol. 99, no. 8, pp. e74–e83, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. Z. Zhou, J. Peng, C. J. Wang et al., “Accelerated senescence of endothelial progenitor cells in hypertension is related to the reduction of calcitonin gene-related peptide,” Journal of Hypertension, vol. 28, no. 5, pp. 931–939, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. P. Wolf, “The nature and significance of platelet products in human plasma,” British Journal of Haematology, vol. 13, no. 3, pp. 269–288, 1967. View at Google Scholar · View at Scopus
  75. M. J. VanWijk, E. VanBavel, A. Sturk, and R. Nieuwland, “Microparticles in cardiovascular diseases,” Cardiovascular Research, vol. 59, no. 2, pp. 277–287, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. R. A. Preston, W. Jy, J. J. Jimenez et al., “Effects of severe hypertension on endothelial and platelet microparticles,” Hypertension, vol. 41, no. 2, pp. 211–217, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. J. M. Sinning, J. Losch, K. Walenta, M. Böhm, G. Nickenig, and N. Werner, “Circulating CD31+/annexin V+ microparticles correlate with cardiovascular outcomes,” European Heart Journal, vol. 32, no. 16, pp. 2034–2041, 2011. View at Publisher · View at Google Scholar · View at PubMed
  78. C. M. Boulanger, N. Amabile, and A. Tedgui, “Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease,” Hypertension, vol. 48, no. 2, pp. 180–186, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. H. Koga, S. Sugiyama, K. Kugiyama et al., “Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease,” Journal of the American College of Cardiology, vol. 45, no. 10, pp. 1622–1630, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. L. Bernal-Mizrachi, W. Jy, J. J. Jimenez et al., “High levels of circulating endothelial microparticles in patients with acute coronary syndromes,” American Heart Journal, vol. 145, no. 6, pp. 962–970, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. A. F. Tramontano, J. O'Leary, A. D. Black, R. Muniyappa, M. V. Cutaia, and N. El-Sherif, “Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway,” Biochemical and Biophysical Research Communications, vol. 320, no. 1, pp. 34–38, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. M. Yamazaki, S. Uchiyama, Y. Xiong, T. Nakano, T. Nakamura, and M. Iwata, “Effect of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents,” Thrombosis Research, vol. 115, no. 3, pp. 211–218, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. B. A. Garcia, D. M. Smalley, H. Cho, J. Shabanowitz, K. Ley, and D. F. Hunt, “The platelet microparticle proteome,” Journal of Proteome Research, vol. 4, no. 5, pp. 1516–1521, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. O. Rubin, D. Crettaz, G. Canellini, J. D. Tissot, and N. Lion, “Microparticles in stored red blood cells: an approach using flow cytometry and proteomic tools,” Vox Sanguinis, vol. 95, no. 4, pp. 289–297, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. C. Banfi, M. Brioschi, R. Wait et al., “Proteome of endothelial cell-derived procoagulant microparticles,” Proteomics, vol. 5, no. 17, pp. 4443–4455, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. R. M. Millis, “Epigenetics and hypertension,” Current Hypertension Reports, vol. 13, no. 1, pp. 21–28, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. I. Bogdarina, S. Welham, P. J. King, S. P. Burns, and A. J. L. Clark, “Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension,” Circulation Research, vol. 100, no. 4, pp. 520–526, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. P. K. Whelton, L. J. Appel, M. A. Espeland et al., “Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE),” Journal of the American Medical Association, vol. 279, no. 11, pp. 839–846, 1998. View at Publisher · View at Google Scholar